Cancer treatment options have become much more sophisticated. From initial diagnostic to next-generation technologies, the way to analyze and understand cancer has improved a lot. Today, healthcare facilities offer individualized treatment options that increase the chances of patient survival and help them lead a better life afterward.
Cancer treatment options have become much more sophisticated. From initial diagnostic to next-generation technologies, the way to analyze and understand cancer has improved a lot. Today, healthcare facilities offer individualized treatment options that increase the chances of patient survival and help them lead a better life afterward.
Cancer or tumor profiling offers the initial information about the genes causing tumors and the mechanism of cancer. The use of cancer profiling is not limited to common cancers including breast cancer and lymphoma but is it proven to be effective in profiling lung, prostate cancer as well as acute leukemia. In short, cancer profiling plays an important role in diagnosis at the molecular level and it helps physicians to make informed decisions and avoid over-treatment of cancer patients, which may lead to other chronic ailments.
According to Allied Market Research, the global cancer/tumor profiling market is expected to reach $82.44 billion by 2023, growing at a CAGR of 18.4% from 2017 to 2023. Surge in adoption of cancer profiling methods, increase in the number of cancer patients, and rise in demand for next-generation sequencing technique in cancer profiling drive the market growth.
Use Of Next-Generation Sequencing In Cancer Profiling
Thanks to advancements in technologies, the healthcare industry has benefitted tremendously from use of next-generation sequencing. Genome profiling based on next-generation sequencing has opened new doors in the cancer profiling market. Moreover, it has increased the knowledge on germline as well as somatic tumor genomics and allowed doctors to offer targeted cancer treatments and avoid over-treating patients.
Particularly, whole-exome and whole-genome cancer sequencing has helped patients that suffer from nearly 38 types of tumors. The tremendous amount of patient data and technological developments such as artificial intelligence and big data has enabled to find patterns and offer viable treatment options.
Next-generation sequencing-based genome profiling has enabled to detect a larger proportion of cancer-driving mutations. This increases survival rate drastically. In addition, driver mutations often cause clonal expansions and prime step of cancer development. Thus, the genome profiling is the most advanced and key method to develop targeted therapies for cancer patients. As the genome profiling offer a detailed assessment of mutational spectrum, doctors can study mutations on a large scale, benefiting millions of cancer patients.
Request for Sample Report for More Insights @ https://www.alliedmarketresearch.com/request-sample/2717
Top Leading Players:
The other key players in the value chain include Claris Life Sciences, Personal Genome Diagnostics, Inc., Perthera, Inc., Foundation Medicine, Inc. V., Strand, ApoCell, Contextual Genomics, Agendia, and GenScript.
Covid-19 Scenario-
Here, it’s worth mentioning that the outbreak of the Covid-19 pandemic led to postponement of Cancer Tumor Profiling procedures, thereby resulting in decreased demand for Cancer Tumor Profiling from the healthcare sector. This factor had a negative impact on the global market, especially during the initial phase. However, the situation has almost gotten back to normalcy and high-end innovations have also been incorporated by the key players. With this drift on board, the market is anticipated to revive really soon.
Having said that, cancer profiling has certainly improved and increased the understand about the development of cancer and how to manage it. It would be a valuable tool to achieve the ultimate goal of medical industry–precision medicine. This would help increase the survival rate of patients and help detect cancer development in the initial stage.